Evidence supporting the use of: Acetylsalicylic acid
For the health condition: Strokes

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Acetylsalicylic acid (aspirin) is scientifically validated for use in the treatment and secondary prevention of certain types of stroke, particularly ischemic stroke. Aspirin works by irreversibly inhibiting the enzyme cyclooxygenase, which in turn reduces the synthesis of thromboxane A2, a molecule involved in platelet aggregation. By decreasing platelet aggregation, aspirin reduces the risk of clot formation in blood vessels supplying the brain, thereby lowering the risk of recurrent ischemic strokes.

A large body of evidence supports the use of aspirin in acute management and secondary prevention of ischemic stroke. The International Stroke Trial and the Chinese Acute Stroke Trial, both large randomized controlled trials, demonstrated that early administration of aspirin after an ischemic stroke modestly reduces the risk of early recurrent stroke and increases the likelihood of survival free of significant disability. Meta-analyses and clinical guidelines (such as those from the American Heart Association and the European Stroke Organization) consistently recommend aspirin as first-line therapy for acute ischemic stroke and for long-term prevention in patients with a history of stroke or transient ischemic attack, unless contraindicated.

It is important to note that aspirin is not recommended for hemorrhagic stroke, as its antiplatelet effects can worsen bleeding. In summary, there is robust scientific evidence for the use of acetylsalicylic acid in the prevention and management of ischemic stroke.

More about Acetylsalicylic acid
More about Strokes

Products containing Acetylsalicylic acid

We currently have no products on Vitabase that contain this ingredient.